Bioinvent AB is a research-based pharmaceutical company focused on discovery and development of antibody-based drugs against cancer. Co. also develops antibody-based drugs in collaboration with partners who finance the development of new drugs and provide it with the right to milestone payments and royalties on sales. Co.'s research is focused on various types of haematological cancer and so-called immunomodulatory therapies, using antibodies with the ability to activate the patient's own immune defences to fight cancer. Co. has three cancer projects in development phase: BI-505 to treat multiple myeloma; BI-1206 to treat haematological cancer; and ADC-1013 to treat metastatic cancer.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.